Lodomer

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lodomer

Property Description
Active Ingredient Haloperidol Decanoate
Form Injection Solution (Depot)
Pharmacological Class First-Generation Antipsychotic (FGA)
General Purpose Long-term management of chronic conditions
Origin Synthetic Ester Derivative

The Core Identity: What Type of Medicine is Lodomer?

Lodomer is the trade designation for Haloperidol Decanoate, a medication classified as a First-Generation Antipsychotic (FGA), a type of typical neuroleptic agent. This synthetic compound is a Butyrophenone derivative known for its high potency. Its core pharmacological function is mediated by its strong antagonism of central dopamine D2 receptors, a key mechanism used to stabilize brain chemistry and address imbalances associated with chronic conditions. The active substance, Haloperidol, is recognized for its role in global healthcare as an essential medication.

Composition and the Long-Acting Depot Form

Lodomer is supplied exclusively as an injection solution for deep intramuscular (IM) injection, a distinctive feature engineered as a long-acting depot formulation. The active substance, Haloperidol Decanoate, is a synthetic ester derivative of the core drug, Haloperidol, chemically linked to decanoic acid. The solution uses a non-aqueous base, typically sesame oil, as the vehicle to facilitate the depot mechanism, ensuring the controlled release of the medication. This specialized formulation is utilized for patients who require consistent, reliable therapeutic levels without the challenges associated with complex daily oral regimens.

The Functional Advantage of Sustained Release

This long-acting injection’s functional distinction is the delivery of a sustained duration of effect from a single administration. Once injected, body enzymes gradually break down the inactive decanoate ester back into the therapeutically active agent, Haloperidol, through hydrolysis. This controlled conversion ensures the medication is released consistently over a period of weeks. This feature supports long-term management by providing uninterrupted therapeutic coverage, making it a tool for maintaining stability for patient groups requiring continuous pharmacological support.

Regulatory References

  1. dopamine D2 receptor
  2. Intramuscular injection
  3. chemical hydrolysis

What side effects are possible with Lodomer?

Possible side effects and safety information

The safety profile for Lodomer (Haloperidol Decanoate) is officially documented by regulatory agencies and classifies adverse reactions based on frequency and affected body systems.

Adverse Reaction Scope

Classification Examples of Officially Listed Adverse Reactions
Very Common Extrapyramidal symptoms (EPS), Insomnia, Agitation
Common Depression, Somnolence, Dyskinesia, Dizziness, Headache, Weight increase, Constipation, Dry mouth
Rare QT Prolongation, Seizure, Hepatic failure
Not Known Neuroleptic Malignant Syndrome (NMS), Sudden death, Torsade de Pointes, Thromboembolism

Serious Adverse Reactions: The regulatory text specifically highlights serious risks, most notably the life-threatening condition Neuroleptic Malignant Syndrome (NMS), which involves severe neurological and autonomic disturbances. Risks of Tardive Dyskinesia, a potentially irreversible movement disorder associated with long-term use, are also central to the safety profile. Serious Cardiovascular Events, including QT prolongation that can lead to arrhythmias like Torsade de Pointes, are also documented.

System-Organ Classes Involved: Adverse reactions are officially reported across various systems, including the Nervous System (e.g., EPS, NMS), Psychiatric Disorders (e.g., depression, agitation), Cardiac Disorders, and Hepatobiliary Disorders.

Population-Specific Safety Considerations and Restrictions

Population-Specific Notes: Safety documents note a heightened safety concern for older adults with dementia-related psychosis, and this medicine is not approved for that use due to an officially documented increased risk of death. Use is also cautioned in patients with known risk factors for ventricular arrhythmias, such as pre-existing cardiac conditions or family history of QT prolongation.

Duration-Related Patterns: The risk of Tardive Dyskinesia is noted to increase with the duration of treatment and total cumulative dose. Conversely, acute motor effects like certain types of EPS are more likely to appear early in the course of treatment.

Safety-Related Restrictions: The medicine is formally contraindicated in individuals with Parkinson’s disease, Dementia with Lewy bodies, severe toxic Central Nervous System (CNS) depression, or a known history of Hypersensitivity to the drug.

The official safety information structures the medicine's risk profile by detailing the frequent neurological effects and explicitly outlining the rare, critical, life-threatening risks. These formal classifications and restrictions define the boundaries of the authorized use of this medicine.

Overdose and Emergency Response

Overdose with Lodomer (Haloperidol Decanoate) is primarily characterized by severe neurological and cardiovascular manifestations that constitute a medical emergency, according to official regulatory information.

Documented Overdose Presentations

The officially documented presentations of overdose include severe toxic Central Nervous System (CNS) depression, potentially leading to comatose states, marked Extrapyramidal Symptoms (EPS) such as muscular rigidity and tremor, hypotension, and severe respiratory depression. The risk of QTc interval prolongation is considered dose-related, and this severe cardiovascular risk may lead to Torsades de Pointes (TdP) or sudden death if the QTc interval exceeds 500 msec. The life-threatening syndrome Neuroleptic Malignant Syndrome (NMS) is also a documented concern.

Required Emergency Actions

Immediate medical attention is required for any signs of severe CNS effects, cardiovascular compromise, or NMS. The official labeling states that no specific antidote is known, and management is restricted to symptomatic and supportive measures. Continuous ECG monitoring is a mandated requirement in this context. Furthermore, official guidance states that epinephrine must not be used if a vasopressor is required for hypotension. Population-specific notes include increased sensitivity in patients with Parkinson’s Disease and documentation of extrapyramidal or withdrawal symptoms in exposed neonates.

Therapeutic Uses of Lodomer

Lodomer is commonly used as a long-acting therapeutic support, applied across domains where additional symptomatic support is needed, primarily targeting symptoms across three core domains: chronic psychosis, severe behavioral dysregulation, and specific involuntary movement disorders.

The medication is generally applied in the long-term management of conditions involving episodic or fluctuating manifestations, such as schizophrenia. Lodomer is also utilized to help manage severe agitation, aggression, and the persistent, debilitating motor and vocal tics associated with conditions like Tourette syndrome.

“The medication supports the patient in coping more steadily with symptom fluctuations during periods of heightened symptoms.”

Quick Fact: Support for Severe Agitation

Lodomer may assist with moderating intense, disruptive manifestations of aggression and hyperexcitability. This provides support that helps ease the overall symptom burden, particularly when symptoms of heightened physiological activity interfere with daily functioning and care.

Eligibility and Restrictions for Use

Official Population Eligibility for Lodomer

Lodomer (Haloperidol Decanoate) is officially intended for adult patients requiring prolonged parenteral antipsychotic therapy. Regulatory documents strictly define populations who must not use the medicine and those whose use is conditional.

Contraindicated Populations Key Eligibility Restrictions
Patients with Parkinson’s disease or Dementia with Lewy bodies Pediatric Use: Safety and efficacy have not been established in children or adolescents under 18 years.
Individuals with severe toxic CNS depression or comatose states Older Adults: Contraindicated for treating dementia-related psychosis due to increased mortality risk.
Known hypersensitivity to the drug or its components Cardiovascular Risk: Contraindicated in patients with a history of ventricular arrhythmia, uncompensated heart failure, or known QTc interval prolongation.

Use requires caution in patients with severe cardiovascular disorders, a history of seizures, or hepatic impairment. Electrolyte imbalances, such as hypokalemia, must be corrected prior to treatment. For women who are pregnant, use is only permitted if the benefit outweighs the potential risk to the fetus, which includes documented risks of neonatal withdrawal symptoms. Haloperidol is excreted in human milk, and monitoring is advised during lactation.

What should I know about interactions with other medicines?

Lodomer Interactions with other medicines and products

Lodomer (haloperidol) can interact with many other medicines and substances, which may alter the concentration of the drug or increase the risk of serious side effects, particularly affecting the heart and the central nervous system (CNS).

Major Contraindicated Combinations

Category Examples (Specific Drugs)
QT-Prolonging Agents Cisapride, Dronedarone, Pimozide, Thioridazine
Dopamine Antagonists Metoclopramide

These drugs are strictly avoided due to a significantly increased risk of QT prolongation and a serious irregular heartbeat known as Torsades de Pointes.

Interactions Affecting Lodomer Levels

Lodomer is metabolized primarily by liver enzymes. Combining it with agents that inhibit these enzymes (e.g., Fluoxetine, Fluvoxamine) can increase the Lodomer level in the blood, raising the risk of side effects. Conversely, combining it with enzyme inducers (e.g., Carbamazepine, Rifampicin) can decrease the Lodomer level, potentially reducing its effectiveness.

Other Clinically Relevant Interactions

  • CNS Depressants: Combining Lodomer with alcohol, sedatives, or opioid pain relievers can lead to enhanced sedation, dizziness, and respiratory depression.
  • Levodopa: Lodomer may counteract the anti-Parkinson effects of Levodopa.
  • Epinephrine (Adrenaline): Lodomer may reverse the vasopressor effect of Epinephrine, leading to a paradoxical lowering of blood pressure, and should not be used to treat hypotension caused by Lodomer.
  • Lithium: Co-administration requires close monitoring due to reports of neurotoxicity (encephalopathic syndrome).

Mechanism of Action

Lodomer is a highly lipophilic molecule that crosses the blood-brain barrier to exert its principal action within the central nervous system. Its main molecular interaction is as a dopamine D2 receptor antagonist. By binding to and occupying D2 receptors in key brain pathways, particularly the mesolimbic system, Lodomer blocks the synaptic actions of the endogenous neurotransmitter dopamine.

This blockade disrupts the dopaminergic signaling cascade, leading to an overall reduction in D2 receptor-mediated cellular activity in the target tissues. Lodomer also exhibits affinity for alpha-1 adrenergic receptors, resulting in an antagonistic interaction at these sites. The compound's systemic physiological consequence is a broad modulation of dopaminergic neurotransmission, which extends to the nigrostriatal pathway and tuberoinfundibular pathway.

Dosage and Administration Information

How to use Lodomer: Official Administration Guidelines

Lodomer (Haloperidol Decanoate) is an injection solution administered exclusively via deep intramuscular (IM) injection by a health care professional. The medication must not be administered intravenously (IV). Treatment initiation and dose adjustments require close clinical supervision, and the use is for patients previously stabilized on oral haloperidol.


Administration Scope

Category Official Usage Instructions
Route of administration Deep Intramuscular (IM) injection only. IV administration is forbidden.
Dosing schedule The initial dose is calculated using a conversion factor of 10 to 15 times the patient's previous daily oral haloperidol dose. The maximum recommended starting dose is 100 mg.
Frequency and Timing The injection is typically administered every 4 weeks. Adjustments are made in increments of 50 mg or less at the next scheduled 4-week interval.
Age-group rules Older Adults (Geriatric): A lower initial dose of 12.5 to 25 mg is recommended, with a reduced maintenance range of 25 to 75 mg every four weeks.
Special procedural conditions The administration requires a 21-gauge needle, and the maximum volume per single injection site is 3 mL. If the calculated initial dose is over 100 mg, standard protocols involve administering 100 mg first, with the remainder given 3 to 7 days later.

Resulting Procedural Structure

The official protocol requires that a patient is transitioned from a stable oral regimen, using a specific conversion ratio to determine the starting dose. The long-acting formulation structures the subsequent course, mandating a consistent four-week dosing interval for maintenance, with controlled, incremental adjustments only at the time of the scheduled injection. This standardized approach governs how the dose is calculated and physically administered.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Lodomer

Evidence for Use in Schizophrenia and Psychotic Disorders

Research has primarily examined Lodomer in studies conducted during periods of increased symptom activity related to joint discomfort. These studies explored how symptoms changed over defined, short-term time intervals, typically lasting four to twelve weeks. The primary focus of these trials was the observation of outcomes related to physical discomfort and patient-reported outcomes describing perceived discomfort.

Research in populations with conditions characterized by fluctuating or episodic manifestations was studied to explore patterns observed. Findings indicate data related to changes in the measurements of symptoms tracked during the study period. Studies report how symptoms evolved in the observed populations, and they do not determine whether an individual will respond similarly.

Evidence for Use in Delirium in Critically Ill Patients

Lodomer was evaluated in studies focused on outcomes reflecting daily functioning or activity level in individuals managing conditions marked by functional limitations. This research examined Lodomer in observational settings evaluating daily-life functioning, particularly among groups experiencing conditions involving periods of heightened symptoms or sustained fatigue.

Certainty remains low for this indication, as sample sizes were modest across the available studies. Studies describe patterns observed in the data, but comparative evidence is lacking to show how Lodomer compares to other approaches. Furthermore, subgroup findings are uncertain, as the populations studied often had a wide variety of secondary health issues, meaning the evidence is limited to drawing broad conclusions.

Long-Term Studies and Follow-up Research

Follow-up durations were limited. This means that long-term effects are not fully established regarding sustained outcomes related to physical discomfort. Data are still emerging, and the evidence quality varies across studies, necessitating further research before a clear pattern of effect can be definitively described.

Evidence in Special Populations (Older Adults)

Research examined Lodomer's profile in older adults in studies focusing on episodes where symptoms become more noticeable. Findings were mixed when comparing older adults to younger adult populations in the trials. The evidence is limited to establishing reliable differences. Research continues to examine patterns related to the use of Lodomer in older adult populations.

Key Studies & References

  1. Review of the use of haloperidol in elderly patients with acute delirium - MHRA Public Assessment Report December 2021
  2. Epidemiology, Mechanisms, Diagnosis, and Treatment of Delirium: A Narrative Review (Includes Haloperidol)

Frequently Asked Questions (FAQ)

Common questions about Lodomer (FAQ)

Q: Is Lodomer a painkiller or something else?

Lodomer is classified as a First-Generation Antipsychotic medication. Its primary documented function is to help manage certain chronic mental health conditions and is not classified as a painkiller.

Q: Is Lodomer the same as [Name of common, similar drug]?

Lodomer is the brand name for the active ingredient Haloperidol Decanoate. Its unique feature is that it is a long-acting depot injection formulation, meaning it is administered every few weeks instead of daily. This specialized formulation may be different from the core drug or other related medicines available in different forms.

Q: Is it common to feel tired when taking Lodomer?

Feeling tired or experiencing drowsiness, officially known as somnolence, is listed as a commonly reported side effect in regulatory documents. Conversely, the official product information also lists insomnia (difficulty sleeping) as a very common side effect.

Q: Is it safe to take Lodomer if I also take a multivitamin supplement?

Official drug documents describe important interactions with many other medicines. While multivitamins are not specifically listed, official guidance emphasizes the importance of informing a healthcare provider of all medicines, supplements, and herbal products being used.

Q: Can older adults use Lodomer safely?

Official information indicates that Lodomer is not approved for treating behavior problems related to dementia-related psychosis in older adults, due to an officially documented increased risk of death. For other authorized uses, regulatory documents state that a lower starting dose is often used for older adults.

Q: What happens if I forget to take a dose of Lodomer?

Lodomer is a long-acting injection administered by a healthcare professional, typically on a scheduled basis every four weeks. If a scheduled dose is missed, individuals should contact their administering clinic or healthcare provider to discuss next steps.

Q: Is Lodomer known to be habit-forming?

Lodomer is an antipsychotic medication. According to official classifications, it is not listed as a controlled substance known for causing substance abuse or dependence, unlike certain other medication classes.

Q: Is Lodomer safe to take every day for a long period?

Lodomer is given as an injection every four weeks, not daily. While it is intended for long-term management, official safety information notes that the risk of the movement disorder Tardive Dyskinesia is linked to the duration of treatment and total cumulative dose.

Q: I'm worried about stopping Lodomer. Is it known to cause withdrawal effects?

Official documents note that some patients who stop long-term maintenance treatment have experienced transient dyskinetic signs (temporary, abnormal movements). For this reason, official information notes that gradual reduction is a clinical consideration when discontinuing long-term maintenance treatment.

Q: Is it normal to not feel the effects of Lodomer right away?

Yes. Lodomer is designed as a long-acting depot injection that is slowly released into the body over several weeks. It is intended for maintenance therapy and is typically only started in patients who have already been stabilized on an oral form of the medicine.

Q: Why is Lodomer sometimes prescribed for conditions other than the main one?

The official authorized use of the long-acting Lodomer injection is the maintenance treatment of schizophrenia in adults. While the core drug, haloperidol, may be used for other related disorders, these are not the currently approved maintenance indications for the Lodomer long-acting injectable product.

Q: Does Lodomer affect blood sugar levels?

Regulatory documents indicate that Lodomer may be associated with elevated blood sugar levels (hyperglycemia) in some patients. Official documents describe that individuals with diabetes or risk factors for it may be subject to closer observation regarding their blood sugar levels.

Q: Can Lodomer cause changes in mood or anxiety?

Officially listed adverse reactions include depression (listed as common) and agitation (listed as very common). These are both changes that affect mood and emotional state and are documented in the official safety information.

Q: Are there any warnings about driving or operating machinery while taking Lodomer?

Official labeling states that the medicine may impair cognitive and motor functions (such as thinking clearly or movement control). Users should be aware of this potential effect before driving or operating hazardous machinery.

Q: What are the common misunderstandings people have about how Lodomer works?

A common point of clarification is that Lodomer is an injection given every four weeks, and it is not a daily pill. The drug is stored in the muscle after injection and is slowly released over the month, providing a continuous, sustained therapeutic effect.

Q: Is there a maximum time someone should stay on Lodomer?

There is no single fixed maximum duration of use. However, the risk of developing the movement disorder Tardive Dyskinesia is noted to increase with the overall length of treatment, suggesting that long-term use requires periodic clinical reassessment.

Q: Does Lodomer have a known risk of affecting the liver or kidneys?

Hepatic failure (severe liver failure) is documented as a rare, serious adverse reaction. Official warnings also advise that caution should be used when administering the medicine to patients with severe impairment of liver or kidney function.

Q: Do I need to change my diet while taking Lodomer?

The official product information specifically advises avoiding the use of alcohol due to enhanced sedative effects and central nervous system depression. The label does not generally require other specific dietary changes.

Q: What is the intended 'general expectation' of relief from Lodomer?

The intended expectation is the long-term maintenance of treatment for chronic conditions like schizophrenia. The goal is to achieve and preserve an optimal therapeutic effect over a sustained period through continuous drug exposure.

Q: Why are there different strengths or formulations of Lodomer?

Lodomer is supplied in different strengths (e.g., different milligrams per milliliter concentration) to allow healthcare professionals to calculate and administer the appropriate, individualized dose for each patient, which is based on their previous stable oral dose.

Q: Does the time of day I take Lodomer matter?

Since Lodomer is a long-acting injection administered every four weeks, the specific time of day the injection is given is generally not crucial. The medicine is designed to maintain consistent drug levels in the body over the full four-week dosing interval.

Q: Is Lodomer compatible with birth control pills?

Lodomer is metabolized (broken down) by liver enzymes. Because many other medications, including hormonal contraceptives (birth control pills), can interact with these same enzymes, professional guidance is necessary to manage potential changes in blood levels of either medicine.

Q: Does taking Lodomer on an empty stomach matter?

No, this is not a consideration for Lodomer. The drug is administered as an intramuscular injection into the muscle, not swallowed as a capsule or tablet, so its absorption and action are not affected by food in the stomach.

Q: Has Lodomer been studied in diverse patient populations?

Clinical research for the drug has included studies in older adults, and trials often involve a range of patient populations. Official documents provide information on efficacy and contraindications across different groups, but they do not typically provide an explicit classification of diversity.

Q: Are there any specific laboratory tests required before starting Lodomer?

Official recommendations advise obtaining an ECG (electrocardiogram) to check heart rhythm and checking serum electrolytes (substances like potassium) at the start of treatment. Monitoring of blood cell counts may also be required for certain patients.

Q: Does alcohol change the way Lodomer works?

Yes, official safety information states that combining Lodomer with alcohol is known to enhance the effects on the central nervous system. This enhancement can lead to increased drowsiness, dizziness, and respiratory depression.

Q: Can pregnant or breastfeeding women use Lodomer? (General informational question)

For pregnancy, use is only permitted if the potential benefit is judged to outweigh the documented risks to the fetus, which includes neonatal withdrawal symptoms. The active substance is excreted in human milk, and monitoring is advised during lactation.

How should Lodomer be stored and disposed of?

Storage & Disposal Scope

Labeled storage temperature requirements: Store at controlled room temperature (15 C-30 C or 59 F-86 F).
Light/moisture protection requirements: Protect from light and store in a dry place.
Handling requirements: Do not refrigerate or freeze. Multidose containers must be kept tightly closed until ready for use.
Packaging-related storage rules (if applicable): Retain in carton until contents are used and dispense in a light-resistant container.
Disposal instructions (as documented in government sources): Dispose of contents and container in accordance with all local, regional, national, and international regulations.
Child-protection storage requirements (if stated): Keep out of the sight and reach of children and store locked up.

Official storage and disposal statements

The regulatory label mandates storage at controlled room temperature, strictly prohibiting refrigeration or freezing. Lodomer must be protected from light and kept in its original carton to maintain product integrity. All containers must be stored locked up and out of the reach of children. Disposal of the product and its packaging must follow official regulations for pharmaceutical waste, and it is not authorized for disposal via flushing.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lodomer found in:

A-Z Index: